Johnson & Johnson (JNJ) — closed signal from November 2, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on January 31, 2026.
Predicted vs. what happened
What happened
Reached its target in 23 days.
The thesis — published November 2, 2025
JNJ looks set for a short-term bounce because it has been pushed down recently while overall mood on the stock is steady. Strong updates from peers Eli Lilly and AbbVie lifted interest across healthcare. JNJ's reliable cash and dividend help limit downside. If interest rates calm, big, steady companies can get a fresh look. If the price climbs back over a nearby ceiling, it could trend back toward normal in 0-3 months.
Primary drivers
- Price looks pushed down, yet investor mood toward JNJ stays steady.
- Peer wins from Eli Lilly and AbbVie boost attention on healthcare.
- Strong cash generation and a steady dividend cushion downturns.
- More investors may rotate into big healthcare names for stability.
How it played out
JNJ: target reached in 23 days
Lyra published JNJ at 187.68 on 2025-11-02 with 10% expected growth and a 205.14 target. The thesis pointed to a pushed-down price with steady investor mood, healthcare attention after peer wins from Eli Lilly and AbbVie, strong cash generation, a steady dividend, and possible rotation into big healthcare names for stability.
Inside the window through 2026-01-31, JNJ reached the target in 23 days. It peaked at 230 on 2026-01-29, with a 22.6% peak gain. It ended at 227.25. The published thesis played out, and the move went beyond the target.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.